Polaryx Therapeutics (NASDAQ:PLYX) Shares Down 16.3% – Here’s Why

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) was down 16.3% during mid-day trading on Wednesday . The stock traded as low as $3.10 and last traded at $3.80. Approximately 335,118 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,747,495 shares. The stock had previously closed at $4.54.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Weiss Ratings assumed coverage on shares of Polaryx Therapeutics in a report on Friday, April 24th. They issued a “sell (e-)” rating on the stock. Maxim Group began coverage on shares of Polaryx Therapeutics in a report on Friday, February 27th. They set a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Polaryx Therapeutics Stock Performance

The stock’s fifty day moving average is $5.28.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.